165 related articles for article (PubMed ID: 35911742)
21. Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility.
Liu X; Zhao Y; Shi H; Zhang Y; Yin X; Liu M; Zhang H; He Y; Lu B; Jin T; Li F
Nat Commun; 2019 Sep; 10(1):4206. PubMed ID: 31562320
[TBL] [Abstract][Full Text] [Related]
22. Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity.
Pfefferlé M; Dubach IL; Buzzi RM; Dürst E; Schulthess-Lutz N; Baselgia L; Hansen K; Imhof L; Koernig S; Le Roy D; Roger T; Humar R; Schaer DJ; Vallelian F
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593065
[TBL] [Abstract][Full Text] [Related]
23. Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid a induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice.
Van De Voort TJ; Felder MA; Yang RK; Sondel PM; Rakhmilevich AL
J Immunother; 2013 Jan; 36(1):29-40. PubMed ID: 23211623
[TBL] [Abstract][Full Text] [Related]
24. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J; Yang Y; Wang G; Liu M
Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
[TBL] [Abstract][Full Text] [Related]
25. A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation.
Mega A; Mebrahtu A; Aniander G; Ryer E; Sköld A; Sandegren A; Backström Rydin E; Rockberg J; Östman A; Frejd FY
MAbs; 2023; 15(1):2223750. PubMed ID: 37332119
[TBL] [Abstract][Full Text] [Related]
26. T-cell-independent antitumor effects of CD40 ligation.
Rakhmilevich AL; Alderson KL; Sondel PM
Int Rev Immunol; 2012 Aug; 31(4):267-78. PubMed ID: 22804571
[TBL] [Abstract][Full Text] [Related]
27. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy.
Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH
J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585
[TBL] [Abstract][Full Text] [Related]
28. Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
Liu HC; Viswanath DI; Pesaresi F; Xu Y; Zhang L; Di Trani N; Paez-Mayorga J; Hernandez N; Wang Y; Erm DR; Ho J; Susnjar A; Liu X; Demaria S; Chen SH; Teh BS; Butler EB; Xuan Chua CY; Grattoni A
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):492-506. PubMed ID: 32768562
[TBL] [Abstract][Full Text] [Related]
29. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization.
White AL; Dou L; Chan HT; Field VL; Mockridge CI; Moss K; Williams EL; Booth SG; French RR; Potter EA; Butts C; Al-Shamkhani A; Cragg MS; Verbeek JS; Johnson PW; Glennie MJ; Beers SA
J Immunol; 2014 Aug; 193(4):1828-35. PubMed ID: 25024386
[TBL] [Abstract][Full Text] [Related]
30. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
31. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
[TBL] [Abstract][Full Text] [Related]
32. The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C; Sykora J; Marschall V; Richards DM; Heinonen K; Redondo Müller M; Thiemann M; Schnyder T; Fricke H; Hill O; Gieffers C
J Immunother; 2018; 41(9):385-398. PubMed ID: 30273198
[TBL] [Abstract][Full Text] [Related]
33. Systemic immune response to a CD40 agonist antibody in nonhuman primates.
Caudell DL; Dugan GO; Babitzki G; Schubert C; Braendli-Baiocco A; Wasserman K; Acona G; Stern M; Passioukov A; Cline JM; Charo J
J Leukoc Biol; 2024 May; 115(6):1084-1093. PubMed ID: 38372596
[TBL] [Abstract][Full Text] [Related]
34. The Use of Anti-CD40 mAb in Cancer.
Remer M; White A; Glennie M; Al-Shamkhani A; Johnson P
Curr Top Microbiol Immunol; 2017; 405():165-207. PubMed ID: 25651948
[TBL] [Abstract][Full Text] [Related]
35. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
[TBL] [Abstract][Full Text] [Related]
36. Design of CD40 agonists and their use in growing B cells for cancer immunotherapy.
Kornbluth RS; Stempniak M; Stone GW
Int Rev Immunol; 2012 Aug; 31(4):279-88. PubMed ID: 22804572
[TBL] [Abstract][Full Text] [Related]
37. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists.
Beatty GL; Li Y; Long KB
Expert Rev Anticancer Ther; 2017 Feb; 17(2):175-186. PubMed ID: 27927088
[TBL] [Abstract][Full Text] [Related]
38. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
Pandey MS; Wang C; Umlauf S; Lin S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
[TBL] [Abstract][Full Text] [Related]
39. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Kashyap AS; Schmittnaegel M; Rigamonti N; Pais-Ferreira D; Mueller P; Buchi M; Ooi CH; Kreuzaler M; Hirschmann P; Guichard A; Rieder N; Bill R; Herting F; Kienast Y; Dirnhofer S; Klein C; Hoves S; Ries CH; Corse E; De Palma M; Zippelius A
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):541-551. PubMed ID: 31889004
[TBL] [Abstract][Full Text] [Related]
40. Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Yu X; Chan HTC; Orr CM; Dadas O; Booth SG; Dahal LN; Penfold CA; O'Brien L; Mockridge CI; French RR; Duriez P; Douglas LR; Pearson AR; Cragg MS; Tews I; Glennie MJ; White AL
Cancer Cell; 2018 Apr; 33(4):664-675.e4. PubMed ID: 29576376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]